CD19CAR T cells: From humble beginnings to cancer immunotherapy's poster child

Cancer Journal (United States)

Volumn 20, Issue 2, 2014, Pages 107-111

  Gardner, Rebecca A ^a   Jensen, Michael C ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CD19; chimeric antigen receptor; Immunotherapy; leukemia; lymphoma; T cell

Indexed keywords

ANTINEOPLASTIC AGENT; CD19 CHIMERIC ANTIGEN RECEPTOR; UNCLASSIFIED DRUG; CD19 ANTIGEN; EPITOPE;

ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL LINEAGE; CELL SURFACE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; NEOPLASMS;

ANTIGENS, CD19; EPITOPES; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTES;

EID: 84897533710     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000030     Document Type: Review

References (65)

1. Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell. 1991;64:891-901.
2. Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the or subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720-724.
3. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3:35-45.
4. Turtle CJ, Hudecek M, Jensen MC, et al. Engineered T cells for anticancer therapy. Curr Opin Immunol. 2012;24:633-639.
5. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010;22:251-257.
6. Barrett DM, Singh N, Porter DL, et al. Chimeric antigen receptor therapy for cancer. Annu Rev Med. 2014;65:333-347.
7. Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer'domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response. Gene Ther. 2010;17:1206-1213.
8. Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev. 2014;257: 127-144.
9. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1- specific chimeric antigen receptor T cells. Clin Cancer Res. 2013;19: 3153-3164.
10. James JR, Vale RD. Biophysical mechanism of T-cell receptor triggering in a reconstituted system. Nature. 2012;487:64-69.
11. Till BG, JensenMC,Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012;119:3940-3950.
12. Haso W, Lee DW, Shah NN, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 2013;121:1165-1174.
13. Hudecek M, Schmitt TM, Baskar S, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1- specific chimeric antigen receptor. Blood. 2010;116:4532-4541.
14. Jensen M. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant. 1998;4:75-83.
15. Jensen MC, Cooper LJN, Wu AM, et al. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy. 2003;5:131-138.
16. Cooper LJN, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus- B-lineage leukemia effect. Blood. 2003;101:1637-1644.
17. Sperling AI, Linsley PS, Barrett TA, et al. CD28-mediated costimulation is necessary for the activation of T cell receptor-gamma delta+ T lymphocytes. J Immunol. 1993;151:6043-6050.
18. Cooper LJN, Al-Kadhimi Z, Serrano LM, et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood. 2005;105:1622-1631.
19. Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007;110:2620-2630.
20. Pule M, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264-1270.
21. Topp MS, Riddell SR, Akatsuka Y, et al. Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigeninduced IL-2 production. J Exp Med. 2003;198:947-955.
22. Brentjens RJ, Latouche J-B, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9:279-286.
23. Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006;66:10995-11004.
24. Hombach AA, Abken H. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28- OX40 signalling. Int J Cancer. 2011;129:2935-2944.
25. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121:1822-1826.
26. Kohn DB, Dotti G, Brentjens R, et al. CARs on track in the clinic. Mol Ther. 2011;19:432-438.
27. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18:676-684.
28. Stone JD, Aggen DH, Schietinger A, et al. A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs). Oncoimmunology. 2012;1:863-873.
29. Brentjens RJR, Davila MLM, Riviere II, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38.
30. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509-1518.
31. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709-2720.
32. Porter DL, Levine BL, KalosM, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-733.
33. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12:269-281.
34. June C, Rosenberg SA, Sadelain M, et al. T-cell therapy at the threshold. Nat Biotechnol. 2012;30:611-614.
35. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550-4557.
36. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118:294-305.
37. Wang X, Berger C, Wong CW, et al. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood. 2011;117:1888-1898.
38. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of Blineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116:4099-4102.
39. Nam SJ, Go H, Paik JH, et al. An increase of M2 macrophages predicts poor prognosis in diffuse large B-cell lymphoma patients treated with Rituximab-CHOP. Leuk Lymphoma. 2014.
40. Yang Z-Z, Ansell SM. The tumor microenvironment in follicular lymphoma. Clin Adv Hematol Oncol. 2012;10:810-818.
41. Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol. 2014;24:71-81.
42. Li MO, Flavell RA. TGF-beta: a master of all T cell trades. Cell. 2008;134:392-404.
43. Bollard CM, Rossig C, CalongeMJ, et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002;99:3179-3187.
44. Prosser ME, Brown CE, Shami AF, et al. Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1: CD28 chimeric receptor. Mol Immunol. 2012;51:263-272.
45. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol. 2012;19:60-71.
46. Chou S-T, Leng Q, Mixson AJ. Zinc finger nucleases: tailor-made for gene therapy. Drugs Future. 2012;37:183-196.
47. Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31:397-405.
48. Boissel S, Jarjour J, Astrakhan A, et al.megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering. Nucleic Acids Res. 2013.
49. Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol. 2013;5(suppl 1):5-11.
50. Hegde M, Corder A, Chow KK, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in Glioblastoma. Mol Ther. 2013;21:2087-2101.
51. Grada Z,Hegde M, Byrd T, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2013;2:e105.
52. Cruz CR, Hanley PJ, Liu H, et al. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010;12:743-749.
53. Sadelain M. Eliminating cells gone astray. N Engl J Med. 2011;365: 1735-1737.
54. Gill S, Porter DL. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road. Expert Opin Biol Ther. 2014;14:37-49.
55. Lupton SD, Brunton LL, Kalberg VA, et al. Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol Cell Biol. 1991;11:3374-3378.
56. Traversari C, Marktel S, Magnani Z, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood. 2007;109:4708-4715.
57. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med. 1996;2:216-223.
58. Jensen MC, Popplewell L, Cooper LJ, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16:1245-1256.
59. Di Stasi A, Tey S-K, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673-1683.
60. Wang X, Chang W-C,Wong CW, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118:1255-1263.
61. Guo ZS, Li Q, Bartlett DL, et al. Gene transfer: the challenge of regulated gene expression. Trends Mol Med. 2008;14:410-418.
62. Toniatti C, Bujard H, Cortese R, et al. Gene therapy progress and prospects: transcription regulatory systems. Gene Ther. 2004;11:649-657.
63. Liang JC, Bloom RJ, Smolke CD. Engineering biological systems with synthetic RNA molecules. Mol Cell. 2011;43:915-926.
64. Chen YY, Jensen MC, Smolke CD. Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. Proc Natl Acad Sci. 2013;107:8531-8536.
65. Bonger KM, Chen L-C, Liu CW, et al. Small-molecule displacement of a cryptic degron causes conditional protein degradation. Nat Chem Biol. 2011;7:531-537.